| Press Release | Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer | Inhibikase Ther... | 0 | 3 months 1 day ago |
| Press Release | Inhibikase Therapeutics Announces 2024 Financial Results and Highlights Recent Activity | Inhibikase Ther... | 0 | 3 months 2 weeks ago |
| Press Release | Inhibikase Appoints Industry Veteran Mark Iwicki as CEO to Drive Next Stage of Companys Growth | Inhibikase Ther... | 0 | 4 months 3 weeks ago |
| Press Release | Inhibikase Therapeutics Completes Enrollment of the Phase 2 201 Trial Evaluating Risvodetinib in Untreated Parkinsons Disease | Inhibikase Ther... | 0 | 1 year 3 weeks ago |
| Press Release | Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs | Inhibikase Ther... | 0 | 1 year 1 month ago |
| Press Release | Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million | Inhibikase Ther... | 0 | 1 year 1 month ago |
| Press Release | Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement | Inhibikase Ther... | 0 | 1 year 2 months ago |
| Press Release | Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension | Inhibikase Ther... | 0 | 1 year 2 months ago |
| Press Release | Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro | Inhibikase Ther... | 0 | 1 year 4 months ago |
| Press Release | Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers | Inhibikase Ther... | 0 | 1 year 5 months ago |
| Press Release | Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib | Inhibikase Ther... | 0 | 1 year 5 months ago |
| Press Release | Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli | Inhibikase Ther... | 0 | 1 year 5 months ago |
| Press Release | Inhibikase Therapeutics Announces Dosing of First Subjects in its '501' Bioequivalence Study of IkT-001Pro | Inhibikase Ther... | 0 | 2 years 7 months ago |
| Press Release | Inhibikase Therapeutics to Present at Piper Sandler 34th Annual Healthcare Conference | Inhibikase Ther... | 0 | 2 years 7 months ago |
| Press Release | Inhibikase Therapeutics Announces FDA Clearance of Investigational New Drug Application for IkT-001Pro for the Treatment of Chronic Myelogenous Leukemia | Inhibikase Ther... | 0 | 2 years 10 months ago |
| Press Release | Inhibikase Therapeutics Announces Dosing of First Patient in its Phase 2a '201' Clinical Trial of IkT-148009 to Treat Parkinson's Disease | Inhibikase Ther... | 0 | 2 years 10 months ago |
| Press Release | Inhibikase Therapeutics Announces Advancement of IkT-148009 Phase 2 '201' Program Following FDA Review | Inhibikase Ther... | 0 | 3 years 1 month ago |
| Press Release | Inhibikase Therapeutics to Participate at the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference | Inhibikase Ther... | 0 | 3 years 2 months ago |
| Press Release | Inhibikase Therapeutics to Host Virtual KOL Investor Event on April 20, 2022 | Inhibikase Ther... | 0 | 3 years 3 months ago |
| Press Release | Inhibikase Therapeutics Reports Full Year 2021 Financial Results and Highlights Recent Period Activity | Inhibikase Ther... | 0 | 3 years 3 months ago |
| Press Release | Inhibikase Therapeutics to Report Full Year 2021 Financial Results on March 31, 2022 | Inhibikase Ther... | 0 | 3 years 3 months ago |
| Press Release | Inhibikase Therapeutics to Participate in the Maxim Group 2022 Virtual Growth Conference | Inhibikase Ther... | 0 | 3 years 3 months ago |
| Press Release | Inhibikase Therapeutics to Present Phase 1/1b Clinical Data at the Upcoming AD/PD Alzheimer's & Parkinson's Diseases Conference | Inhibikase Ther... | 0 | 3 years 4 months ago |
| Press Release | Inhibikase Therapeutics Highlights 2022 Pipeline Goals and Milestones | Inhibikase Ther... | 0 | 3 years 6 months ago |
| Press Release | Inhibikase Therapeutics Announces Publication Highlighting Mechanism of Disease and the Potential of Oral c-Abl Kinase Inhibitor Therapy for the Treatment of Parkinson's Disease | Inhibikase Ther... | 0 | 3 years 7 months ago |
